Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-22

Study Completion Date

2018-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC. Multiple logistic regression analysis will be performed to evaluate the association between statin therapy and the risk of HCC recurrence after LT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Learning Model for the Prediction of Post-LT HCC Recurrence

NCT05200195

Liver Transplant Disorder Liver Cancer Recurrent Cancer

COMPLETED

AFP Model and Liver Transplantation.

NCT03775863

Liver Carcinoma Liver Transplant Disorder

COMPLETED

Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma

NCT06114251

Liver Transplant; Complications

COMPLETED

Liquid Biopsy-based Monitoring System for Relapse of HCC After Liver Transplantation: A Multi-center and Prospective Study

NCT03708705

Hepatocellular Carcinoma

UNKNOWN

A Worldwide Score for Hepatocellular Cancer and Liver Transplantation

NCT03595345

Liver Cancer Dropout, Patient Recurrence

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Statin group

Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation

Statin

Intervention Type DRUG

Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.

Non-statin group

the administration of statins for less than 30 days after liver transplantation

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Statin

Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who received LT at the Severance Hospital from 2006 to 2016.

Exclusion Criteria

* early postoperative mortality (defined as death within 2 months after LT without signs of tumor recurrence)
* patient with distant lymph node metastasis confirmed within 1 month after LT
* Patients younger than 20 years of age
* patients who had LT for cirrhosis without confirmed HCC

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No